By Barbara Obstoj-Cardwell. Editor
Research news was prominent last week, first with US healthcare giant Johnson & Johnson presenting new data on nipocalimab in the treatment of generalized myasthenia gravis (MS), pitching it against argenx’ Fc Rn blocker Vyvgart. Cartesian Therapeutics also reported positive top-line results for Descartes-08 in patients with myasthenia gravis, as well as a $130 financing. However, Roche released disappointing Phase II/III clinical trial results for its tiragolumab in combination with Tecentriq for non-small cell lung cancer (NSCLC), leading the Swiss pharma giant to halt the study. On the regulatory front, Eli Lilly gained long-awaited approval from the US Food and Drug Administration for its Alzheimer’s disease drug donanemab, to be marketed by the US pharma major under the trade name Kisunla.
J&J: Nipocalimab benefit/risk in MG questionable vs Vyvgart
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze